Bill Bradley

Bill Bradley Email and Phone Number

Senior Director of Translational Research and Clinical Biomarkers @ Antares Therapeutics
Boston, MA, US
Bill Bradley's Location
Lexington, Massachusetts, United States, United States
Bill Bradley's Contact Details
About Bill Bradley

▪ 10+ years of industry experience in big pharma and small biotech settings ranging from early discovery to phase 2 clinical development of molecularly targeted small molecule inhibitors in oncology therapeutic area▪ Experience building companies and departments, including leading a multifunctional team of scientists and associates, and building internal and external Translational Research department infrastructure▪ Track record of translating novel biological findings into differentiated clinical biomarker strategies as translational lead for 3 small molecule inhibitor clinical programs (MCT1 and 2 EZH2 inhibitors)▪ Preclinical oncology expertise, with practical experience in epigenetics, chromatin biology, kinases and signal transduction, synthetic lethality, immuno-oncology, and identification of mechanisms of therapeutic resistance▪ Success in establishing meaningful collaborations with key scientific leaders and clinical investigators

Bill Bradley's Current Company Details
Antares Therapeutics

Antares Therapeutics

View
Senior Director of Translational Research and Clinical Biomarkers
Boston, MA, US
Bill Bradley Work Experience Details
  • Antares Therapeutics
    Senior Director Of Translational Research And Clinical Biomarkers
    Antares Therapeutics
    Boston, Ma, Us
  • Scorpion Therapeutics
    Senior Director Of Translational Research & Clinical Biomarkers
    Scorpion Therapeutics Apr 2024 - Present
  • Cyteir Therapeutics
    Senior Director, Head Of Translational Research
    Cyteir Therapeutics Feb 2022 - Jan 2024
    Lexington, Ma, Us
    - Discovered MOA of CYT-0851 as an inhibitor of monocarboxylate transporter (MCT) mediated lactate transport- Translational and biomarker lead for CYT-0851; implemented and managed biomarker strategy for phase 1/2 clinical trials in heme and solid cancers- Designed novel biomarker assays, including CTC- and ctDNA-based assay, and IHC, qPCR, and other NGS-based assays for both tumor and liquid biopsies- Built and managed Translational Research and Bioinformatics functions, and external In Vivo Pharmacology- Recruited and mentored 4 PhD scientists/associate directors; established and managed company’s external network of in vivo pharmacology, bioinformatics, and biomarker CRO’s and consultants, and SRA’s with academic collaborators- Supported executive leadership team during IPO (June 2021): writing scientific sections of S1, and writing/presenting responses to investors’ questions during crossover financing round
  • Cyteir Therapeutics
    Director, Head Of Translational Research
    Cyteir Therapeutics Feb 2020 - Feb 2022
    Lexington, Ma, Us
  • Constellation Pharmaceuticals
    Associate Director Of Translational Sciences
    Constellation Pharmaceuticals May 2017 - Feb 2020
    - Translational lead for EZH2 Inhibitor Franchise (lirametostat/CPI-1205 and tulmimetostat/CPI-0209)- Managed preclinical research group to understand MOA, expand indications, identify predictive and PD biomarkers, and mechanisms of resistance- Implemented biomarker strategy for CPI-1205 phase 1/2 clinical trials in metastatic castration-resistant prostate cancer, a combination trial with IO checkpoint inhibitors, and a non-Hodgkin’s B cell lymphoma trial- Worked with CSO to establish Translational Research function as a spin-out of Discovery Biology function- Supported executive leadership team during IPO (July 2018) contributing to scientific sections of S1
  • Constellation Pharmaceuticals
    Senior Scientist
    Constellation Pharmaceuticals Feb 2015 - May 2017
    - Co-managed preclinical biology for EZH2 inhibitor program- Discovered target engagement gene signature for EZH2 inhibitors; developed/implemented assays to establish PK/PD relationship for CPI-1205 including gene signature, IHC and CTC-based histone modification assays
  • Constellation Pharmaceuticals
    Scientist Ii
    Constellation Pharmaceuticals Feb 2014 - Feb 2015
    - Discovered synergistic combination of EZH2 inhibitors and type I interferons; explored clinical feasibility- Utilized multi-omics approach (RNA-/ChIP-seq) to advance understanding of EZH2’s role in cancer development through silencing of pro-apoptotic genes- Championed internal adoption of CETSA technique, CRISPR technology, and PRISM cell panel screening
  • Constellation Pharmaceuticals
    Scientist
    Constellation Pharmaceuticals Oct 2012 - Feb 2014
    - Preclinical biology lead for demethylase program during Genentech collaboration; coordinated research efforts with Genentech counterpart to support target validation, indication selection, and biomarker and stratification hypothesis generation
  • Roche Pharmaceuticals
    Postdoctoral Fellow
    Roche Pharmaceuticals Jan 2010 - Sep 2012
    Switzerland 🇨🇭 , Ch
    - Member of preclinical vemurafenib team (Zelboraf, the first BRAF V600E-specific inhibitor approved for treatment of metastatic melanoma in August 2011) - Identified mechanism of acquired resistance to vemurafenib in melanoma cell lines- Generated model system to identify escape mechanisms utilized by melanoma to evade combination therapies- Investigated molecular basis of divergent vemurafenib efficacy observed between melanoma and colorectal cancers in human trials

Bill Bradley Skills

Cancer Research Signal Transduction Protein Kinases Drug Discovery Biochemistry Molecular Biology Cell Biology Target Identification Assay Development Biomarkers In Vitro In Vivo Epigenetics Translational Research Translational Science

Bill Bradley Education Details

  • Yale University
    Yale University
    Molecular Biophysics & Biochemistry
  • Boston College
    Boston College
    Biochemistry

Frequently Asked Questions about Bill Bradley

What company does Bill Bradley work for?

Bill Bradley works for Antares Therapeutics

What is Bill Bradley's role at the current company?

Bill Bradley's current role is Senior Director of Translational Research and Clinical Biomarkers.

What is Bill Bradley's email address?

Bill Bradley's email address is bb****@****rma.com

What is Bill Bradley's direct phone number?

Bill Bradley's direct phone number is +161757*****

What schools did Bill Bradley attend?

Bill Bradley attended Yale University, Boston College.

What skills is Bill Bradley known for?

Bill Bradley has skills like Cancer Research, Signal Transduction, Protein Kinases, Drug Discovery, Biochemistry, Molecular Biology, Cell Biology, Target Identification, Assay Development, Biomarkers, In Vitro, In Vivo.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.